Longeveron Inc. (LGVN)

NASDAQ: LGVN · IEX Real-Time Price · USD
3.290
+0.040 (1.23%)
At close: Jul 19, 2024, 4:00 PM
3.260
-0.030 (-0.91%)
After-hours: Jul 19, 2024, 7:59 PM EDT
1.23%
Market Cap 31.59M
Revenue (ttm) 978,000
Net Income (ttm) -21.62M
Shares Out 9.60M
EPS (ttm) -9.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,531,027
Open 3.130
Previous Close 3.250
Day's Range 2.900 - 3.420
52-Week Range 0.771 - 35.600
Beta 0.41
Analysts Strong Buy
Price Target 12.00 (+264.74%)
Earnings Date Aug 9, 2024

About LGVN

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was i... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2021
Employees 24
Stock Exchange NASDAQ
Ticker Symbol LGVN
Full Company Profile

Financial Performance

In 2023, Longeveron's revenue was $709,000, a decrease of -41.98% compared to the previous year's $1.22 million. Losses were -$22.21 million, 17.9% more than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for LGVN stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target
$12.0
(264.74% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for ...

2 days ago - GlobeNewsWire

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for ...

3 days ago - GlobeNewsWire

Longeveron stock opened 100% up on Wednesday: explore why

Longeveron Inc (NASDAQ: LGVN) soared 100% on Wednesday after its Lomecel-B received RMAT designation from the Food & Drug Administration.  Lomecel-B is the company's investigational treatment for Alzh...

11 days ago - Invezz

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Longeveron® Announces U.S. FDA Grants Lomecel-B(TM) Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

11 days ago - GlobeNewsWire

Neha Motwani Elected to Longeveron® Board of Directors

MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic agi...

12 days ago - GlobeNewsWire

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.

13 days ago - GlobeNewsWire

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for ...

4 weeks ago - GlobeNewsWire

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.

4 weeks ago - GlobeNewsWire

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for ...

4 weeks ago - GlobeNewsWire

Why has Longeveron stock tripled in two days?

Longeveron Inc (NASDAQ: LGVN) rallied another 50% on Thursday as investors continued to celebrate the positive update of its Lomecel-B study.  Why is it significant for Longeveron stock?

5 weeks ago - Invezz

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron launches contract development and manufacturing business for stem cell therapies. 15,000 sf state-of-the-art GMP facility with 8 cleanrooms.

6 weeks ago - GlobeNewsWire

Longeveron® to Attend BIO International Convention 2024

MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic agin...

7 weeks ago - GlobeNewsWire

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update

Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.

2 months ago - GlobeNewsWire

Longeveron Announces Board of Directors Planned Transitions

Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron Board Dr. Roger Hajjar, former head of R&D at Ring Therapeutics,...

2 months ago - GlobeNewsWire

Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024...

2 months ago - GlobeNewsWire

Longeveron to Present at the Planet MicroCap Showcase

MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Plan...

3 months ago - GlobeNewsWire

Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering

MIAMI, April 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and ...

3 months ago - GlobeNewsWire

Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Longeveron raises gross proceeds of ~$6.2 M from exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its common stock.

3 months ago - GlobeNewsWire

Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)

Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer's Disease has been accepted for two presentations at AAIC.

3 months ago - GlobeNewsWire

Longeveron Announces Closing of $5.2 Million Public Offering

MIAMI, April 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and ...

3 months ago - GlobeNewsWire

Longeveron Announces Pricing of $5.25 Million Public Offering

MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chro...

3 months ago - GlobeNewsWire

Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals

MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company's CEO, Wa'el Hashad...

3 months ago - GlobeNewsWire

Longeveron Announces 1-for-10 Reverse Stock Split

MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, ...

4 months ago - GlobeNewsWire

Longeveron Reports Year-End 2023 Results and Provides Corporate Update

Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B™  in HLHS Continues Enrollment; Completion of St...

5 months ago - GlobeNewsWire

Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024

MIAMI, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, a...

5 months ago - GlobeNewsWire